How should we treat a patient with early Parkinson's disease?

International Journal of Clinical Practice
S Tsouli, S Konitsiotis

Abstract

Parkinson's disease (PD) is characterised by the progressive degeneration of dopaminergic nigro-striatal neurons and severe striatal dopaminergic deficiency, leading to bradykinesia. Levodopa was the first drug used for PD treatment and is still considered the most useful weapon for the control of PD symptoms. However, levodopa treatment induces motor complications, which is considered as a major problem as the disease progresses. Dopamine agonists, catechol-O-methyltransferase inhibitors and monoamine oxidase B inhibitors are some more recently developed drug categories which are expected to have a more favourable effect on motor complications. The choice of the best initial treatment in PD remains a controversial matter. Early therapeutic decisions in PD should balance the need for efficient short-term symptom control against long-term complication profile. The individualisation of the treatment seems to be the key for the best approach of early PD patients.

References

Aug 1, 1990·Journal of Neuroscience Research·P P Michel, F Hefti
Jan 1, 1986·Movement Disorders : Official Journal of the Movement Disorder Society·N QuinnC D Marsden
Jan 1, 1984·Clinical Neuropharmacology·J G Nutt, J H Fellman
Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·J Knoll
May 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·C E Clarke
Mar 1, 1995·Journal of Neurology, Neurosurgery, and Psychiatry·Y Ben-Shlomo, M G Marmot
Jan 1, 1993·Neuroepidemiology·Z X Zhang, G C Román
Sep 30, 1993·The New England Journal of Medicine·D B Calne
Jan 21, 1993·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Jan 1, 1996·Alzheimer Disease and Associated Disorders·P Leber
May 5, 1998·Neurology·Y Agid
Jun 20, 1998·Neurology·D E Silver, S Ruggieri
Jul 10, 1998·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·D Muralikrishnan, K P Mohanakumar
Nov 11, 1999·Archives of Neurology·L V MetmanT N Chase
Dec 10, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·Y AgidE Tolosa
Jan 21, 2000·Pharmacotherapy·M Stacy
Feb 19, 2000·Archives of Neurology·C W Olanow
Jun 1, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·A D SiderowfM B Stern
Jun 1, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·D A Di MonteW J Langston
Jun 8, 2001·Clinical Neuropharmacology·L V MetmanT N Chase
Jun 8, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·J E Ahlskog, M D Muenter
Jun 23, 2001·Drugs & Aging·W D Le, J Jankovic
Mar 23, 2002·Neurology·Joseph Jankovic
Apr 3, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN Parkinson Study Group
Jun 27, 2002·Expert Opinion on Pharmacotherapy·Claire Henchcliffe, Cheryl Waters
Sep 21, 2002·Lancet·Y AgidY Mizuno

❮ Previous
Next ❯

Citations

May 3, 2013·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Sandro Zambito MarsalaAngelo Antonini
Jan 10, 2012·Social Science & Medicine·Fadhila MazanderaniJohn Powell
Dec 3, 2010·Clinical Neuropharmacology·Sofia PappaSpiridon Konitsiotis
Jan 4, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Jesse BastiaensMelissa J Nirenberg
Jan 13, 2019·Journal of Neural Transmission·Nobutaka HattoriRyosuke Takahashi
Jan 29, 2019·Journal of Neural Transmission·Nobutaka HattoriRyosuke Takahashi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
D A Di MonteW J Langston
BMJ : British Medical Journal
C E Clarke
BMJ : British Medical Journal
Christopher J McDermott, Pamela J Shaw
© 2021 Meta ULC. All rights reserved